FDA Approves Rasonque, First RAS Inhibitor for Metastatic Pancreatic Cancer

The FDA cleared daraxonrasib for the most common form of advanced pancreatic cancer, acting months ahead of its review deadline.

Share
Laboratory research into pancreatic cancer, the disease targeted by the newly approved RAS inhibitor.
Laboratory research into pancreatic cancer, the disease targeted by the newly approved RAS inhibitor. Foto: Anastassia Anufrieva via Unsplash